The Oregon Cancer Center (OCC), a matrix Clinical Cancer Center at Oregon Health Science University (OHSU) with 173 members, was awarded a CCSG (P30) two years ago. Since that time, the Center has been assigned 33,000 square feet of new space for its headquarters (11,000 square feet) and a new basic research building (22,000 square feet). Having focused on strengthening our clinical research infrastructure, we have successfully recruited senior leaders in clinical cancer research, two of whom are now principal investigators of multi- institutional study groups and serve on the Leadership Council of the Center. In the past two years of CCSG support, our investigators- institutional therapeutic clinical trials have increased fourfold, we are now ranked fourth in accruals to SWOG studies, and we have tripled CCG accruals. Our experimental Therapeutics program has focused directly on transplantation and cancer immunology, in part responding to criticisms in the prior review and input from the external advisory team. Now known is the Transplantation/Immunology Program, this group focuses on immunological tolerance in transplantation and cancer immunology. Because of the cohesiveness of this smaller, more focused group this program has the highest frequency of inter- and intra-programmatic publications in our Center. In cancer control, we have recruited seasoned investigators to the Center and have reached a critical mass in four focus areas driving support of this program's investigator-initiated research portfolio from $300,000 annually to more than $5 million annually in two years. In the past three years we have recruited 42 new members, and, in the next five years, we will recruit no fewer than 27 more in collaboration with 10 departments and institutes. The mission of our Center is to support research designed to identify molecular defects in neoplastic cells and to exploit such knowledge to develop more effective strategies for diagnosis, treatment, prevention, and control of malignant diseases. Translational research projects have increased in all five of the programs, and. in the past two years, some of our best scientific research projects have already moved into Phase I clinical trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oregon Health and Science University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6

Showing the most recent 10 out of 277 publications